Evidence map›Paper›PMID 35630591›Full record

ArticleMolecules (Basel, Switzerland)2022

The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells.

Jing-Jing Qu, Lin-Lin Shi, Yan-Bing Wang, Jing Yan, Tian Shao, Xin-Qi Hao, Jia-Xiang Wang, Hong-Yu Zhang, Jun-Fang Gong, Bing Song

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jing-Jing QuCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Lin-Lin ShiCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.ORCID 0000-0001-9089-2388
Yan-Bing WangCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Jing YanCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Tian ShaoCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.ORCID 0000-0002-1333-2878
Xin-Qi HaoCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Jia-Xiang WangCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Hong-Yu ZhangCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Jun-Fang GongCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.
Bing SongCollege of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China.ORCID 0000-0001-5159-6703
First Affiliated Hospital of Zhengzhou University · CN

Funding

China Postdoctoral Science Foundation 2018M642773; 2018M642773Foundation of He'nan Educational Committee 18A180007Henan provincial natural science foundation of excellent youth fund 212300410069National Natural Science Foundation of China 31801092, 22101267
6 · The paper itself

Abstract

We report that the pincer nickel complexes display prostate cancer antitumor properties through inhibition of cell proliferation. Notably, they display better antitumor properties than cisplatin. Mechanistic studies reveal that these pincer nickel complexes trigger cell apoptosis, most likely due to cell cycle arrest. Interestingly, these complexes also inhibit androgen receptor (AR) and prostate-specific antigen (PSA) signaling, which are critical for prostate cancer survival and progression. Our study reveals a novel function of pincer nickel complexes as potential therapeutic drugs in prostate cancer.

Indexed as

Antineoplastic AgentsProstatic NeoplasmsCell Line, TumorHumansMaleNickelPelvisAntineoplastic AgentsNickelandrogen receptornickelpincer complexprostate cancerPSA

Identifiers

PMID35630591
PMCPMC9147786
OpenAlexW4280540865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.